

Phuong Khanh (P.K.) Morrow, MD, FACP

OFFICE ADDRESS: Amgen, Inc.
One Amgen Center Drive
Mail Stop 38-2-B
Thousand Oaks, CA 91320

INDUSTRY EXPERIENCE

2014 - present Oncology Therapeutic Area Head, US Medical Organization
Amgen
Thousand Oaks, CA

2013-2015 Global Development Lead, Neupogen[®]/Neulasta[®]
Amgen
Thousand Oaks, CA

2012-2013 US Medical Lead, Neupogen[®]/Neulasta[®]
Amgen
Thousand Oaks, CA

ACADEMIC APPOINTMENTS

2006-2012 Assistant Professor, Department of Breast Medical Oncology,
The University of Texas MD Anderson Cancer Center
Houston, TX

HOSPITAL APPOINTMENTS

1994-1996 Clinical Pharmacist
University of Texas Medical Branch
Galveston Texas

POSTGRADUATE TRAINING

2003–2006 Hematology/Oncology Fellowship
The University of Texas MD Anderson Cancer Center
Houston, TX
-Clifton D. Howe Award (Fellow of the Year) recipient – 2004
-Lyndon Baines Johnson Chief Fellow – 2005-2006

2000-2003 Internal Medicine Residency
Baylor College of Medicine
Houston, TX

EDUCATION

- 1996-2000 M.D. University of Texas Medical School at Houston
Houston, TX
-Alpha Omega Alpha Honor Medical Society
- 1990-1994 B.S. University of Houston (Pharmacy),
Houston, TX

HONORS AND AWARDS

1. **Alpha Omega Alpha Honor Medical Society**, The University of Texas Medical School at Houston, 1999
2. **American Medical Women's Association Janet M. Glasgow Achievement Citation**, The University of Texas Medical School at Houston, 2000
3. **Finalist for the Gold-Headed Cane Award for Humanism in Medicine**, The University of Texas Medical School at Houston, 2000
4. **Eli Lilly Award for Superb Humanistic Qualities As A Resident in Internal Medicine**, Baylor College of Medicine, 2003
5. **Clifton D. Howe Award for Clinical Excellence in Medical Oncology**, The University of Texas MD Anderson Cancer Center, 2004
6. **American Society of Clinical Oncology Young Investigator Award**, 2005
7. **Lyndon Baines Johnson Chief Fellow**, The University of Texas MD Anderson Cancer Center, 2005-2006
8. **America's Top Oncologists**, 2011-2015
9. **Fellow of the American College of Physicians**, 2012-current

CREDENTIALS

American Board of Internal Medicine, Internal Medicine

American Board of Internal Medicine, Medical Oncology

ACADEMIC ADMINISTRATIVE APPOINTMENTS/RESPONSIBILITIES

1. Associate Medical Director, Beth Sanders Moore Young Breast Cancer Survivors' Program, University of Texas MD Anderson Cancer Center, Houston, TX, 7/2006-3/2009
2. Medical Director, Young Breast Cancer Survivors Program, University of Texas MD Anderson Cancer Center, Houston, TX, 3/2009-02/2012
3. Breast Medical Oncology Curriculum Associate Director, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-02/2012
4. Faculty Host Advocate to Spartanburg Regional Healthcare System, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-02/2012
5. Associate Medical Director, Breast Cancer Survivorship Program, University of Texas MD Anderson Cancer Center, Houston, TX, 3/2009-02/2012
6. Member, Breast Center Leadership Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 5/2009-02/2012
7. Member, Cancer Prevention Center Steering Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 5/2009-02/2012
8. Committee Chair, Division of Cancer Medicine, Comprehensive Cancer Control, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2010-02/2012


9. Member, Cytokines & Supportive Oncology Working Group, University of Texas MD Anderson Cancer Center, Houston, TX, 2006–2007
10. Member, NCI Phase II Contract Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 2006–2012
11. Co-Chair, Chemotherapy-induced Nausea and Vomiting Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007–2/2008
12. Alternative Member, Serum Bank Oversight Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007–8/2010
13. Member, Extravasation Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 5/2008–5/2009
14. Member, Pharmacy and Therapeutics Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008–8/2009
15. Member, Clinical Research Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2010–2/2012
16. Member, Survivorship Research Advisory Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011–2/2012
17. Reviewer, Study Section Review Committee for Clinical Translational and Population-Based Research Projects under the Institutional Research Grants Program, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011–2/2012

RESEARCH PROTOCOLS



(b) (4)

5. Principal Investigator, Randomized, Double-Blind, Placebo-Controlled Trial of Palonosetron/Dexamethasone with or without Dronabinol for the Prevention of Chemotherapy-induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy, 2006-0841, 2006–2007, National Cancer Institute



(b) (4)

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. **Morrow PK**, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. *J Clin Oncol*. 2011 Aug 10;29(23):3126-32.
2. **Morrow PK**, Tarrand JJ, Taylor SH, Kau SW, Theriault RL, Hortobagyi GN, Broglio KR, Hahn KM. Effects of chronic hepatitis C infection on the treatment of breast cancer patients. *Ann Oncol*. 2010 Jun;21(6):1233-6.
3. **Morrow PK**, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M, Schmelter T, Wang Y, Hortobagyi GN, Vahdat LT. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. *Breast Cancer Res Treat*. 2010 Oct;123(3):837-42.
4. **Morrow PK**, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Kwiatkowski DN, Hortobagyi GN. Effect of age and race on quality of life in young breast cancer survivors. *Clin Breast Cancer* 2014 Apr;14(2):e21-31.
5. **Morrow PK**, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM. Effect of CYP2D6 polymorphisms on breast cancer recurrence. *Cancer* 2012 Mar 1;118(5):1221-7.
6. **Morrow PK**, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. *Cancer*. 2012 Sep 1;118(17):4098-104.
7. Li X, Luthra R, **Morrow PK**, Fisher MD, Reiner M, Barron RL, Langeberg WJ. Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle. *J Oncol Pharm Pract*. 2015 Sep 15.
8. Havrilesky LJ, Reiner M, **Morrow PK**, Watson H, Crawford J. A review of relative dose intensity and survival in patients with metastatic solid tumors. *Crit Rev Oncol Hematol*. 2015 Mar;93(3):203-10.
9. Lyman GH, Reiner M, **Morrow PK**, Crawford J. The Effect of Filgrastim or Pegfilgrastim on Survival Outcomes of Patients With Cancer Receiving Myelosuppressive Chemotherapy. *Ann Oncol*. 2015 Jul;26(7):1452-8.
10. Weycker D, Li X, Barron R, Wu H, Morrow PK, Xu H, Reiner M, Garcia J, Mhatre SK, Lyman GH. Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use. *J Natl Compr Canc Netw*. 2015 Aug;13(8):979-86.
11. Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, **Morrow PK**, Barron RL, Asmar L, Saravanan S, Li Y, Garcia J, Lyman GH. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. *J Natl Compr Canc Netw*. 2015 Nov;13(11):1383-93.
12. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, **Morrow PK**, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the Phosphoinositide 3-kinase Pathway for the Treatment of Patients with Metastatic Metaplastic Breast Cancer. *Ann Oncol*. 2015 Jul;26(7):1346-52.
13. Lyman GH, Dale DC, Legg JC, Abella E, **Morrow PK**, Whittaker S, Crawford J. Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? *Cancer Med*. 2015 Aug;4(8):1153-60.
14. Langeberg WJ, Siozon CC, Page JH, **Morrow PK**, Chia VM. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. *Support Care Cancer*. 2014 Aug;22(8):2167-75.
15. Sano D, Fooshee DR, Zhao M, Andrews GA, Frederick MJ, Galer C, Milas ZL, **Morrow PK**, Myers JN. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. *Head Neck*. 2011 Mar;33(3):349-58.
16. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, **Morrow PK**, Koenig K, Kurzrock R. Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. *J Clin Oncol*. 2011 Jul 1;29(19):e572-5.

17. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, **Morrow PK**, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. *Clin Breast Cancer*. 2011 Oct;11(5):325-31.
18. Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, **Morrow PK**, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. *Cancer J*. 2014 Jan-Feb;20(1):8-14.
19. Yang BB, **Morrow PK**, Wu X, Moxness M, Padhi D. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. *Cancer Chemother Pharmacol*. 2015 Apr 17.
20. Camacho LH, Frost CP, Abella E, **Morrow PK**, Whittaker S. Biosimilars 101: considerations for U.S. oncologists in clinical practice. *Cancer Med* 2014 Aug;3(4):889-99.
21. **Morrow PK**, Kim ES. New biological agents in the treatment of advanced non-small cell lung cancer. *Semin Respir Crit Care Med*. 2005 Jun;26(3):323-32.
22. **Morrow PK**, Hoff PM. Does the addition of oxaliplatin increase the risk of capecitabine-induced cardiotoxicity? *Nat Clin Pract Oncol*. 2006 Feb;3(2):76-7.
23. **Morrow PK**, Theriault RL. Pregnancy after the diagnosis of breast cancer. *Clin Breast Cancer*. 2006 Jun;7(2):173-5.
24. Reyes-Gibby CC, **Morrow PK**, Buzdar A, Shete S. Chemotherapy-Induced Peripheral Neuropathy as a Predictor of Neuropathic Pain in Breast Cancer Patients Previously Treated with Paclitaxel. *Pain*. 2009 Nov;10(11):1146-50.
25. Murthy RK, **Morrow PK**, Theriault RL. Bone biology and the role of the RANK ligand pathway. *Oncology (Williston Park)*. 2009 Dec;23(14 Suppl 5):9-15.
26. Escalante CP, Kallen MA, Valdres RU, **Morrow PK**, Manzullo EF. Outcomes of a Cancer-Related Fatigue Clinic in a Comprehensive Cancer Center. *J Pain Symptom Manage*. 2010 Apr;39(4):691-701.
27. Reyes-Gibby C, **Morrow PK**, Bennett MI, Jensen MP, Shete S. Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool. *J Pain Symptom Manage*. 2010 May;39(5):882-9.
28. Reyes-Gibby CC, Anderson KO, **Morrow PK**, Shete S, Hassan S. Depressive Symptoms and Health-Related Quality of Life in Breast Cancer Survivors. *J Womens Health (Larchmt)*. 2012 Mar;21(3):311-8.
29. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, **Morrow PK**, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. *Clin Exp Metastasis*. 2013 Jun;30(5):631-42.
30. Camacho LH, Frost CP, Abella E, **Morrow PK**, Whittaker S. Biosimilars 101: considerations for U.S. oncologists in clinical practice. *Cancer Med*. 2014 Aug;3(4):889-99.

Invited Articles

1. **Morrow PK**, Hortobagyi GN. Management of breast cancer in the genome era. *Annual Rev Med* 60:153-165, 2009.
2. **Morrow PK**, Zambrana F, Esteva FJ. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. *Breast Cancer Res* 11(4):207, 2009.
3. **Morrow PK**. Commentary on the Accuracy of Perceived Risk of Recurrence Among Patients. *Breast Diseases: A Yearbook Quarterly*, 2010.
4. **Morrow PK**. Commentary on Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. *Breast Diseases: A Yearbook Quarterly*, 2011.
5. **Morrow PK**, Mattair DN, Hortobagyi GN. Hot Flashes: A Review of Pathophysiology and Treatment Modalities. *Oncologist* 16(11):1658-64, 2011. e-Pub 10/2011.

Other Articles

1. **Morrow P**, Kim E. A patient with advanced non-small cell lung cancer treated with a regimen including a multitargeted antifolate. *Case Reports in Lung Cancer* 3:1-8, 2004.
2. **Morrow P**, Kies M. A patient with squamous cell carcinoma of the head and neck treated with radiation and concomitant cetuximab. *Case Studies in Oncology* 6:1-7, 2004.
3. **Morrow P**. Case Study: Breast Cancer Treatment and Chronic Hepatitis. *Clinical Issues & Therapeutic Advances* 7(1):5-6, May 2008, 5/2008.
4. **Morrow PK**, Hortobagyi GN. Breast Cancer, Primary Invasive. *BMJ IN Practice*, 8/2008.

Abstracts

1. **Morrow P**, Theriault RL, Hortobagyi GN, Rolston KH, Tarrand JJ, Taylor SH, Thomas ES, Gwyn KM. Clinical outcomes of breast cancer patients with hepatitis C: A case series. *Proc Am Soc Clin Oncol* 23(16S):747, 6/2005.
2. **Morrow P**, Glisson BS, Ginsberg LE, Lippman SM, Kies MS, Blumenschein GR, Ayuste RC. A phase I dose escalation study of Pemetrexed in patients with advanced head and neck squamous cell carcinoma. *Proc Am Soc Clin Oncol* 25(18S):6055, 6/2007.
3. **Morrow PK**, Diver L, Provencher S, Luoh S, Petrella TM, Giurescu M, Fielding L, Wang Y, Hortobagyi GN, Vadhat L. Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC). *Journal of Clinical Oncology* 27(15S):1083, 6/2009.
4. Kallen MA, Duffy J, Valdres R, **Morrow PK**, Manzullo E, Escalante CP. Patient Apathy and Increased Symptom Burden: Initial Experiences in a Cancer-Related Fatigue (CRF) Clinic. *Supportive Care in Cancer* 18(3):S95-S96 (#06-038), 6/2010
5. Escalante CP, Kallen MA, Duffy J, Valdres R, **Morrow PK**, Manzullo E. Does Apathy Impact Cancer Patient Symptom Burden. *ASCO Annual Meeting, American Society of Clinical Oncology*, 2010, 6/2010.
6. Escalante CP, Meyers C, Reuben JM, Wang X, Qiao MS, Manzullo E, Alvarez R, **Morrow PK**, Gonzalez-Angulo A, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C. A Randomized, Double Blind, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in Cancer-Related Fatigue. *ASCO Annual Meeting, American Society of Clinical Oncology, Chicago, IL*, 6/2012
7. Vogl FD, Guinigundo AS, Maxwell C, Vanni L, Badre S, **Morrow PK**. Prophylactic naproxen or loratadine for bone pain in breast cancer patients receiving chemotherapy and pegfilgrastim: a randomized, phase 2 study (NOLAN) Amgen:20110147 - NCT:01712009, *MASCC International Symposium on Supportive Care in Cancer, Berlin, Germany*, 06/2013.
8. Vogl FD, Guinigundo AS, Maxwell C, Vanni L, Badre S, **Morrow PK**. The effect of patient education on reported bone pain in breast cancer patients receiving chemotherapy and pegfilgrastim: a randomized, single-blind study (VINE) Amgen:20110148 – NCT:01752907, *MASCC International Symposium on Supportive Care in Cancer, Berlin, Germany*, 06/2013.

Book Chapters

1. **Morrow P**, Theriault R. The use of bisphosphonates in breast cancer. In: Disease of the Breast Updates. 7, 1-14, 2004.
2. **Morrow P**, Theriault RL, Hortobagyi GN. Cancer and Pregnancy. In: Cancer Medicine. 12th ed. BC Decker: Ontario Canada, 941-948, 2006.
3. **Morrow PK**, Theriault RL. General NCCN Guidelines. In: Kuerer's Breast Surgical Oncology. McGraw-Hill: Columbus, OH, 2009.
4. Murthy RK, **Morrow PK**. Breast Cancer in Young Women. In: Advanced Therapy of Breast Disease: Manchester, NH. In Press.
5. **Morrow P**, Kim ES. Targeted agents in non-small cell lung cancer. In: Atlas of Lung Cancer. In Press.

Journal Reviewer

1. Invited reviewer, Cancer, 2006–02/2012
2. Invited reviewer, Clinical Breast Cancer, 2007–02/2012
3. Invited reviewer, The Oncologist, 2007–02/2012
4. Invited Reviewer, Cancers, 2010–02/2012

CONFERENCES AND SYMPOSIA

Presentations at National or International Conferences

1. Lyman GH, Dale DC, Legg JC, **Morrow PK**, Whittaker S, Crawford J. A multicenter observational study comparing physician-assessed febrile neutropenia (FN) risk and prediction-model severe neutropenia (SN) or FN risk in patients (pts) with nonmyeloid malignancies. 2014 ASCO Annual Meeting.
2. Bhor M, Li X, Favret A, **Morrow PK**, Denduluri N, Barron RL, Shanmugapriya S, Girardi V, Patt DA, Li Y, Lyman GH. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received (neo)adjuvant chemotherapy in community oncology practices. 2014 ASCO Annual Meeting
3. Lyman GH, Reiner M, **Morrow PK**, Crawford J. Survival outcomes of patients (pts) who received filgrastim (fil) or pegfilgrastim (peg) in clinical trials. 2014 ASCO Annual Meeting.
4. Crawford J, Reiner M, **Morrow PK**, Lyman GH. Incidence of febrile neutropenia and effectiveness of pegfilgrastim prophylaxis in patients with advanced-stage solid tumors receiving chemotherapy. 2013 ASCO Annual Meeting.
5. Grunberg S, Munsell M, **Morrow PK**, Giguere JK, Ule UJ, Saccaro SJ, Onitilo AA, Metzner-Sadurski JK, Fisch M. Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea. 2012 ASCO Annual Meeting.
6. Litton JK, Hodge S, Mattair D, Ramirez MM, **Morrow PK**, Gonzalez-Angulo AM, Barnett CM, Hortobagyi GN, Theriault RL. Outcomes of children exposed to chemotherapy in utero for breast cancer. 2011 ASCO Annual Meeting.
7. **Morrow PK**, Bevers TB, Zandra F, Russell L. Multidisciplinary care of the breast cancer survivor: An innovative approach. 2011 ASCO Breast Symposium.
8. Puzstai L, Moulder SL, Litton JK, Valero V, Ueno NT, **Morrow PK**, Dotter K, Mattair D, Strauss LC, Symmans WF. Gene-signature-based patient selection for dasatinib therapy in metastatic breast cancer (MBC). 2010 ASCO Annual Meeting.
9. **Morrow PK**, Broxson AC, Munsell M, Basen-Engquist K, Rosenblum CK, Nguyen LH, Schover LR, Hahn K, Litton JK, Hortobagyi GN. Long-term effects of the diagnosis and treatment of breast cancer upon young breast cancer survivors. 2011 ASCO Annual Meeting, Chicago, IL, 6/2007.
10. **Morrow PK**, Glisson BS, Ginsberg LE, Lippman SM, Kies MS, Blumenschein GR, Ayuste RC. A phase I dose escalation study of pemetrexed in patients with advanced head and neck squamous cell cancer, 2007 ASCO Annual Meeting, Chicago, IL, 6/2007
11. **Morrow PK**, Theriault RL, Hortobagyi GN, Rolston KH, Tarrand JJ, Taylor SH, Thomas ES, Gwyn KM. Clinical outcomes of breast cancer patients with hepatitis C: A case series. Effects of hepatitis C on the treatment of breast cancer, 2007 ASCO Breast Symposium Meeting, San Francisco, CA, 9/2007
12. **Morrow PK**. Emerging Trends in Adjuvant Therapy for Breast Cancer, United Resource Networks' 16th Annual National Clinical Conference, Minneapolis, MN, 9/2007

13. **Morrow PK.** New Horizons in the Biologic Therapies in the Treatment of Breast Cancer, National Congress of the Mexican Oncology Society, Tuxtla Guiterrez, Chiapas, Mexico, 10/2007
14. **Morrow PK.** Targeted Therapies for Metastatic Breast Cancer, Metastatic Breast Cancer Network Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2007
15. **Morrow PK.** Genomic Profiling of Node Positive and Negative Breast Cancer Patients, The University of Texas M.D. Anderson Cancer Center and M.D. Anderson Physicians Network Fourth Annual Symposium, The University of Texas MD Anderson Cancer Center, Boston, MA, 8/23/2008
16. **Morrow PK.** Recent Advances in the Treatment of Metastatic Breast Cancer, The University of Texas M.D. Anderson Cancer Center and M.D. Anderson Physicians Network Fourth Annual Symposium, The University of Texas MD Anderson Cancer Center, Boston, MA, 8/23/2008
17. **Morrow PK,** Diver S, Provencher L, Luoh SW, Petrella T, Gurescu M, Fielding L, Wang L, Hortobagyi GN, Vahdat L. Phase II study of sagopilone (ZK-EPO), a novel epothilone, in patients with recurrent metastatic breast cancer, 2009 ASCO Annual Meeting, American Society of Clinical Oncology, Orlando, FL, 6/2009
18. **Morrow PK,** Wulf GM, Booser DJ, Moore JA, Flores PR, Krop IE, Winer EP, Hortobagyi GN, Esteva FJ. Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant HER2-overexpressing breast cancer, 2010 ASCO Annual Meeting, American Society of Clinical Oncology, Chicago, IL, 6/2010
19. **Morrow PK,** Moulder SL, Baetz T, D'Aloisio S, Fernetich G, Saja B, Karan S, Freeman B, Barret E, Guthrie K, Kass C, Chia SKL. A Phase I Study to Assess the Safety, Tolerability, and PK of ARRY-380 - an Oral Inhibitor of HER2, ASCO Breast Symposium, ASCO Breast Symposium, Washington D.C., 10/1/2010
20. **Morrow PKH,** Broxson AC, Munsell M, Basen-Enquist K, Rosenblum CK, Nguyen LH, Schover LR, Hahn KME, Litton JK, Hortobagyi GN. Long-term effects of the diagnosis and treatment of breast cancer upon young breast cancer survivors, 2011 ASCO Annual Meeting, American Society of Clinical Oncology, Chicago, IL, 2011
21. **Morrow PK.** HER-2 Directed Therapies: Adjuvant or Neoadjuvant?, MD Anderson Cancer Center and MD Anderson Physicians Network Symposium, MD Anderson Cancer Center and MD Anderson Physicians Network, San Francisco, CA, 7/31/2011
22. **Morrow PK.** Making Sense of Multigene Assays in Practice, MD Anderson Cancer Center and MD Anderson Physician's Network Symposium, MD Anderson Physician's Network, San Francisco, CA, 7/31/2011
23. **Morrow PK,** Zandstra F, Palos G, Bowe AC, Guzman M, Russell L, Bevers TB. Multidisciplinary care of the breast cancer survivor, ASCO Breast Symposium, American Society of Clinical Oncology, San Francisco, CA, 9/9/2011

Seminar Invitations from Other Institutions

Trends in Adjuvant Therapy in Breast Cancer, Gibbs Cancer Center, Spartanburg, SC, 11/2007

Other Presentations at State and Local Conferences

1. **Morrow PK.** Updates from the 2006 San Antonio Breast Cancer Symposium, Beth Sanders Moore Young Breast Cancer Survivors Winter Meeting, Beth Sanders Moore Young Breast Cancer Survivors, Houston, TX, 1/2007
2. **Morrow PK.** Breast Cancer Staging and Natural History of Breast Cancer, Breast Cancer Workshop, Light and Salt Cancer Support Network, Houston, TX, 6/2007
3. **Morrow PK.** Updates from the 2007 San Antonio Breast Cancer Symposium, Beth Sanders Moore Young Breast Cancer Survivors Program, Houston, TX, 3/1/2008
4. **Morrow, PK.** Breast Cancer Survivorship, Breast Cancer Survivorship in 2010: What is your Doctor Looking For?, M.D. Anderson Physicians Network, M.D. Anderson Network Cancer Survivorship Conference, Houston, TX, 9/24/2010
5. **Morrow, P.K.** Breast Cancer Survivorship in 2010, The Cancer Center at Presbyterian, Cancer Update for Primary Care Physicians, Albuquerque, NM, 10/8/2010

6. **Morrow, PK.** Assessing the Long-Term Effects of Diagnosis and Treatment of Breast Cancer Upon Young Breast Cancer Survivors, Institutional Grand Rounds, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/21/2011
7. **Morrow PK, Babiera GV, Terreffe W.** Your Questions Answered: A Multidisciplinary Panel Of Breast Cancer Experts, MD Anderson Cancer Center Cancer Survivorship Conference, MD Anderson Network, MD Anderson Network, Houston, TX, 9/16/2011
8. **Morrow PK.** Facing Breast Cancer, Herald Cancer Association, Houston, TX, 10/29/2011
9. **Morrow PK.** Breast Cancer Survivorship - Guidelines/Management of the Breast Cancer Survivor, Cancer Survivorship Conference, MD Anderson Cancer Center, Houston, TX

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

1. American Society of Clinical Oncology, Voting Member, 2004–present
2. American College of Physicians, Fellow, 2012-present
3. American College of Physicians, Member, 2010-2012
4. Southwest Oncology Group, Member, 2007–2012
5. American Medical Association, Member, 2009–2012
6. National Comprehensive Cancer Network Corporate Council – 2015-present